Abstract
The antipsychotic market generated global sales of US$15.5 billion, accounting
for 23% of global CNS sales in 2005. This chapter of CNS Drug Discoveries
focuses on schizophrenia.
The antipsychotic market generated global sales of US$15.5 billion, accounting
for 23% of global CNS sales in 2005, growing by 11% year on year. The market
has evolved since the 1950s when the first conventional or typical
antipsychotics were introduced, followed by atypical antipsychotics in the
late 1990s with better tolerability profiles.
Schizophrenia is one of the major psychotic disorders and the WHO estimates
that approximately 1% of the world' s population at some point in life will be
affected by schizophrenia, while 0.5% of all people will be afflicted by the
disease at any given time (around 24 million people worldwide). The total
economic burden of schizophrenia in 1990 was estimated to be US$32.5 billion
(equivalent to US$47.6 billion today after consumer price index adjustment).
Conversely, the total costs of anxiety disorders, whilst ten times more
prevalent than schizophrenia, amounted to US$42 billion annually.
Global antipsychotic market
The antipsychotic market has witnessed strong growth during the last five
years as the atypical antipsychotics have become established in the market and
companies have sought to expand their utility in the acute and long-term
treatment of schizophrenia and bipolar disorders. While atypical
antipsychotics now account for over 80% of global sales there has been a
radical slow down in the last 18 months due to concerns over safety. This
finding has resulted in the FDA requesting additional warnings to be placed on
all the leading atypical antipsychotic labels.
By 2012, the leadership position within the antipsychotic market will change
as today' s leading brands go off patent and companies launch their third
generation atypical antipsychotics and new manufacturers enter the market.
View Cart
